The book delves into the rising incidence of colorectal cancer in Tunisia and emphasizes the role of inflammation in its development. It highlights the potential of specific serum biomarkers—TNF, IL1, IL6, IL8, IL10, and IL22—as indicators for patient prognosis. By identifying those at high risk for recurrence or in need of aggressive treatment, the study proposes a new, simplified prognostic score based on these biomarkers, aiming for improved patient monitoring and outcomes.
